[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"streptococcal-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:streptococcal-infections":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100599531","phase-1-a-study-to-evaluate-safety-reactogenicity-and-immunogenicity-of-the-gsk-4-component-strep-a-vaccine-with-aluminum-hydroxide-alum-or-as37-in-healthy-young-adults-100599531",false,"NCT07085702","A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults","A Phase 1 Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Vaccine Against Group A Streptococcus Pyogenes (Strep A) With Alum or AS37 in Healthy Adults 18 to 25 Years of Age in Australia","Inclusion Criteria:\n\n* Participants, who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., completion of electronic diaries \\[eDiaries\\], return for follow-up visits).\n* Written or witnessed\u002Fthumb-printed informed consent obtained from the participant prior to performance of any study-specific procedure.\n* Healthy participants as established by medical history, clinical examination, and laboratory assessments.\n* Satisfies all screening requirements.\n* Male and female participants between and including 18 and 25 years of age at the time of informed consent.\n* Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as premenarche, postmenopause, or had current bilateral tubal ligation or occlusion, hysterectomy, or bilateral ovariectomy.\n* Female participants who are of childbearing potential may be enrolled in the study if the participant:\n\n  * has practiced adequate contraception for 1 month prior to study intervention administration, and\n  * has a negative pregnancy test on the day of study intervention administration, and\n  * has agreed to continue adequate contraception during the entire study intervention administration period and for 1 month after completion of the study intervention administration series.\n* Male participants who are sexually active with a female partner of childbearing potential are eligible to participate if they agree to have their partner use a highly effective method of contraception for 1 month prior to the first study intervention administration until 1 month after completion of the study intervention administration series.\n* Male participants must refrain from donating sperm for 1 month prior to the first study intervention administration until 1 month after completion of the study intervention administration series.\n* Participants seronegative for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C at Screening.\n\nExclusion Criteria:\n\n* History of rheumatic fever or rheumatic heart disease during the lifetime of the participant as confirmed during interview with the participant or as documented in medical records.\n* Recent history of pharyngitis in the last four (4) weeks will be excluded. These participants can be rescreened once the recent pharyngitis passes the 4-weeks period. Participants with symptoms of acute pharyngitis at Screening will be tested with a Strep A rapid antigen test. Those with positive results will be excluded.\n* Progressive, unstable, or uncontrolled clinical conditions.\n* History (known or suspected) of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Hypersensitivity (e.g., allergy) to medicinal products or medical equipment anticipated to be used in this study.\n* Clinical conditions that represents a contraindication for IM vaccination or blood draws.\n* Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.\n* Acute disease and\u002For fever (defined as temperature \\>=38.0°C) at the time of enrollment.\n* Any Grade \\>=2 and\u002For clinically significant hematological and\u002For biochemical laboratory abnormality.\n* Any echocardiographic\u002FDoppler Echo findings consistent with carditis at Screening.\n* Recurrent history or uncontrolled neurological disorders or seizures.\n* Medical history or family history of autoimmune disease and other pIMDs.\n* Family history of acute rheumatic fever.\n* Acute or chronic illness, or clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality.\n* Any other clinical condition that might pose additional risk to the participant due to participation in the study.\n* Administration of long-acting immune-modifying drugs (e.g., infliximab) at any time prior to the administration of the first dose of study intervention(s) or planned administration during the study period.\n* Prior receipt of an experimental Strep A vaccine.\n* Use of any investigational or nonregistered product (drug, vaccine, or medical device) other than the study interventions during the period starting 30 days before the first dose of study intervention (Day -30 to Day 1), or their planned use during the study period.\n* Receipt of a vaccine not foreseen by the study protocol administered during the period starting at 21 days before the first dose of study intervention (28 days before the first dose, in case of live vaccines) and ending after the last dose of study intervention administration.\n* Administration of immunoglobulins and\u002For any blood products or plasma derivatives, or bone marrow transplantation, during the period starting 3 months before administration of the first dose of study intervention(s) or planned administration during the study period.\n* Chronic administration (defined as \\>14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first dose of study intervention. For corticosteroids, this means prednisone equivalent \\>=20 mg\u002Fday for adult participants. Inhaled, topical, intra-articular, and intranasal steroids are allowed.\n* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug, vaccine, or invasive medical device).\n* Pregnant or lactating female participant.\n* Participant who is planning to become pregnant or planning to discontinue contraceptive precautions.\n* History of or current chronic alcohol consumption and\u002For drug abuse.\n* Any study personnel or their immediate dependents, family, or household members.",true,"ALL","18 Years","25 Years",{"count":21,"type":22},108,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant. The Strep A vaccine will be tested for the first time in humans, in healthy young adults 18 to 25 years of age. The study will also assess if the vaccines have any immediate reactions and if they induce an immune response. A low, medium, and high dose of each formulation of the vaccine will be assessed in sequence.",[28],"Streptococcal Infections",[30,31,32,33,34,35,36],"Strep A","Streptococcus pyogenes","Safety","Reactogenicity","Immunogenicity","Healthy Adults","Australia","RECRUITING","2026-08-07",{"date":40,"type":41},"2026-08-11","ACTUAL",{"date":43,"type":41},"2025-07-29",{"date":45,"type":22},"2027-06-29",{"name":47,"class":48},"GlaxoSmithKline","INDUSTRY",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":17,"minAge":57,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100642701","a-clinical-trial-of-the-13-valent-pneumococcal-polysaccharide-conjugate-vaccine-crm197tetanus-toxoid-100642701","NCT07648641","A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197\u002FTetanus Toxoid)","Phase IV Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197\u002FTetanus Toxoid)","Inclusion Criteria:\n\n* Participants in the 2-month-old (minimum 6 weeks) group from the previous Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector) (Protocol No.: CS-CTP-PCV)\n* The legal guardian or authorized representative is willing to provide identification documents\n* The legal guardian or authorized representative has provided informed consent, voluntarily signed the informed consent form, and is able to comply with the requirements of the clinical study protocol\n* The interval since the last dose of the primary vaccination series is ≥4 years\n\nExclusion Criteria:\n\n* Failure to complete blood draws at 1 and 2 years post-vaccination\n* Administration of any pneumonia vaccine after completion of the full vaccination series\n* Body temperature ≥37.3°C\n* Any other factors deemed by the investigator to render the participant unsuitable for participation in the clinical trial","5 Years",{"count":59,"type":22},100,"OBSERVATIONAL","This clinical study will enroll 100 participants from the 2-month-old (minimum 6 weeks) group who previously participated in the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector) (Protocol No.: CS-CTP-PCV), with 50 participants in each of the treatment and control groups, and who have completed blood sample collection for the 1-year and 2-year immunogenicity studies. All participants will have 3.0-3.5 mL of venous blood collected for the immunogenicity study.",[63,28,64],"Pneumococcal Infections","Bacterial Infections",[66,67,63,68],"PCV13","13 valent Pneumococcal conjugate vaccine","Immune persistence","NOT_YET_RECRUITING","2026-08-03",{"date":72,"type":41},"2026-08-05",{"date":74,"type":22},"2026-09-01",{"date":76,"type":22},"2027-12-01",{"name":78,"class":48},"CanSino Biologics Inc.",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100619326","factors-associated-with-mortality-in-streptococcal-anginosus-bacteremia-100619326","NCT07343167","Factors Associated With Mortality in Streptococcal Anginosus Bacteremia","SGA","Inclusion Criteria:\n\n* Major subject (≥18 years old)\n* Hospitalized between January 1, 2019, and December 31, 2024, in one of the participating centers\n* Having presented during the study period at least one positive blood culture for Streptococcus anginosus, Streptococcus constellatus, or Streptococcus intermedius in a laboratory at a participating center\n\nExclusion Criteria:\n\n* Refusal to participate in the study",{"count":87,"type":22},400,"Streptococcal anginosus infections (S. constellatus, S. anginosus, and S. intermedius) are characterized by their severity, linked to high mortality and frequent infectious complications. Several studies in the literature highlight this severity, with mortality rates estimated at around 15%.\n\nThe aim of this research is to identify the factors associated with mortality in Streptococcal anginosus bacteremia.",[28],[28,91,92],"Streptococcal Anginosus Bacteremia","Streptococcal anginosus infections","2026-01-06",{"date":95,"type":41},"2026-01-15",{"date":97,"type":41},"2025-09-08",{"date":99,"type":22},"2027-03-08",{"name":101,"class":102},"University Hospital, Strasbourg, France","OTHER",1]